Scarica l'app Stockscreener
4.37
6.42%
-0.30
Pre-mercato:
4.38
0.010
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.67
Aprire:
$4.7037
Volume 24 ore:
6.81M
Relative Volume:
2.75
Capitalizzazione di mercato:
$430.80M
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-32.96
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
+22.75%
1M Prestazione:
-6.62%
6M Prestazione:
-10.08%
1 anno Prestazione:
-42.65%
Intervallo 1D:
$4.281
$4.7037
Intervallo di 1 settimana:
$3.45
$5.41
Portata 52W:
$3.305
$8.80
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Confronta GDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.37 | 1.78B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
284.02 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
73.28 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
64.36 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.04 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.09 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
Raymond James Downgrade Shakes GoodRx as Market Reacts - StocksToTrade
GoodRx Shares Slide Amid Profit-Taking After 30% Surge - AInvest
GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On? - inkl
GoodRx Stock Rises 29% Following Novo Nordisk Partnership - AInvest
GoodRx stock holds Neutral rating at Mizuho amid Novo Nordisk partnership - Investing.com
Mizuho Reiterates Neutral Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider
Hims & Hers Health Stock Falls Amid Rival GoodRx's Deal with Novo Nordisk - AInvest
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access - Benzinga
GoodRx Holdings Stock Price, Quotes and Forecasts | NASDAQ:GDRX - Benzinga
Top Stocks to Watch: Intel, Palo Alto Networks, Goodrx, Applied Digital, and Duolingo - AInvest
Intel, Palo Alto Networks, Goodrx, Applied Digital And Duolingo: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
GoodRx Earnings Call: Growth Amid Challenges - MSN
Is Novo Nordisk deal the much-needed catalyst for Goodrx stock? - TradingView
Why GoodRx (GDRX) Stock Is Trading Up Today - Yahoo Finance
GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning? (NASDAQ:GDRX) - Seeking Alpha
Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers - Reuters
GoodRx Is Soaring On A Novo Nordisk Deal. Should You Buy GDRX Stock Here? - Barchart.com
From Doubt To Action: Why I Bought Novo Nordisk After Earnings (NYSE:NVO) - Seeking Alpha
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday - inkl
Meta's reported shake-up, Hims & Hers sinks on GoodRx–Novo deal - Yahoo Finance
GoodRx stock rating maintained at Underperform by BofA despite new offering - Investing.com
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets - inkl
Stock Movers: Novo Nordisk, GoodRX, CVS - Bloomberg.com
GoodRx Holdings (GDRX) Stock: Shares Jump 35% on Novo Nordisk Partnership - parameter.io
BofA Securities Reiterates Underperform Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider
GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month - Yahoo Finance
Why GoodRx Holds Promise Amidst Mixed Signals - StocksToTrade
Novo Nordisk partners with GoodRx for $499 monthly Ozempic, Wegovy (GDRX:NASDAQ) - Seeking Alpha
GoodRx Stock Soars 13.14% on Strategic Partnerships - AInvest
GoodRx partners with Novo Nordisk to offer Ozempic, Wegovy for $499 monthly - StreetInsider
$499 Monthly Ozempic Access: GoodRx and Novo Nordisk Launch Groundbreaking Affordability Program - Stock Titan
3 Promising Penny Stocks With Market Caps Under $2B - simplywall.st
Is it time to cut losses on GoodRx Holdings Inc.M&A Rumor & Pattern Based Trade Signal System - Newser
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth - MSN
GoodRx Raises Guidance with Double-Digit Growth Driven by Pharma Partnerships - AInvest
Quant Strategy Flags GoodRx Holdings Inc. for Entry2025 Sector Review & Weekly High Potential Alerts - metal.it
GoodRx Holdings' (NASDAQ:GDRX) Performance Is Even Better Than Its Earnings Suggest - simplywall.st
Why Investors Shouldn't Be Surprised By GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 25% Share Price Plunge - 富途牛牛
GoodRx Holdings Inc. Stock Poised for Technical ComebackJuly 2025 Rallies & Community Verified Swing Trade Signals - thegnnews.com
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2025 Earnings Call Transcript - Insider Monkey
UBS Keeps Hold Rating on GoodRx Holdings with $4.25 Target - AInvest
GoodRx Q2 Earnings Miss Expectations Due to Rite Aid Bankruptcy and PBM Disruptions. - AInvest
GoodRx stock price target lowered to $4.25 from $5.25 at UBS - Investing.com Australia
GoodRx Holdings Inc. (GDRX) PT Lowered to $4.25 at UBS - StreetInsider
Deutsche Bank Adjusts GoodRx Price Target to $6 From $8, Maintains Hold Rating - MarketScreener
Raymond James Downgrades GoodRx Holdings to Outperform From Strong Buy, Adjusts Price Target to $5 From $9 - MarketScreener
GoodRx Holdings: Strategic Growth and Revised Projections Support Buy Rating Despite Short-term Adjustments - TipRanks
GoodRx Holdings: Buy Rating Maintained Despite Short-term Adjustments - AInvest
GoodRx Holdings Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Elanco Animal Health (ELAN) - The Globe and Mail
GoodRx Holdings Inc. stock chart pattern explainedVolume Confirmed Setup with Entry Confidence - Newser
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Goodrx Holdings Inc Azioni (GDRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | 10% Owner |
Jul 03 '25 |
Sale |
4.80 |
10,677 |
51,226 |
0 |
2.52%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):